201218-07-7

Upstream product

• 383-63-1 ethyl trifluoroacetate, 
• 18437-66-6 N-(t-butoxycarbonyl)-4-chloroaniline 
• 340-07-8 N-(trifluoroacetyl)piperidine 

Downstream Products

• 202721-01-5 tert-butyl 4-chloro-2-(7-chloro-1,1,1-trifluoro-2-hydroxyhept-3-yn-2-yl)phenylcarbamate 
• 201218-08-8 tert-butyl 4-chloro-2-(4-cyclopropyl-1,1,1-trifluoro-2-hydroxybut-3-yn-2-yl)phenylcarbamate 
• 177530-93-7 rac-efavirenz 
• 209414-27-7 (2S)-2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol 
• 154598-52-4 efavirenz 
• 202721-00-4 5-chloro-α-n-butyl-α-trifluoromethyl-2-t-butoxycarbonylamino-benzenemethanol 

Relevant academic research and scientific papers

METHOD FOR THE MANUFACTURE OF EFAVIRENZ

This invention relates to a method for the manufacture of optically pure (S)-6- chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1 -benzoxazin- 2-one. Specifically, this invention relates to a flow synthesis method for the manufacture of (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4- (trifluoromethyl)-2H-3,1 -benzoxazin-2-one.

Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors

The present invention describes novel methods for the synthesis of benzoxazinone compounds which are useful as human immunodeficiency virus (HIV) reverse transcriptase inhibitors. The benzoxazinone of the formula: is particularly effective in the treatment of HIV.